Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: A potential factor predisposing to thrombosis and its persistence

Circulation

Volumn 97, Issue 22, 1998, Pages 2213-2221

  Sobel, Burton E ^a,c   Woodcock Mitchell, Janet ^a   Schneider, David J ^a   Holt, Robert E ^b   Marutsuka, Kousuke ^a   Gold, Herman ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Coronary disease; Diabetes mellitus; Fibrinolysis; Insulin; Thrombosis

Indexed keywords

INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA DERIVATIVE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; AGED; ARTICLE; ATHERECTOMY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DIET THERAPY; DISEASE PREDISPOSITION; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESTENOSIS; THROMBOSIS;

EID: 0032499636     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.22.2213     Document Type: Article

References (24)

1. Schneider DJ, Sobel BE. Determinants of coronary vascular disease in patients with type 2 diabetes mellitus and their therapeutic implications. Clin Cordial. 1997;20:433-440.
2. Kannel WB, D'Agostino RB, Wilson P, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experiments. Am Heart J. 1990;120:672-676.
3. Swislocki ALM, Huffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens. 1989;2:419-423.
4. DeFronzo RA. Insulin secretion, insulin resistance, and obesity. Int J Obes. 1982;6(suppl l):73-82.
5. Despres J-P, Lamarche B, Mauglege P, Cantin B, Dagenais GR, Moorjani S, Lupien PJ, Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
6. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D, Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level and relative body weight in normal and obese subjects. Metabolism. 1986;35:250-253.
7. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
8. Schneider DJ, Sobel BE, Augmentation of synthesis of plasminogen activator inhibitor type-1 by insulin and insulin-like growth factor type-1: implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci U S A. 1991;88:9959-9963.
9. Writing Group for the Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Five-year clinical and functional outcome comparing bypass surgery and angioplasty in patients with multivessel coronary disease: a multicenter randomized trial. JAMA. 1997;277:715-721.
10. Sobel BE. Potentiation of vasculopathy by insulin: implications from an NHLBI Clinical Alert. Circulation. 1996;93:1613-1615.
11. Schneider DJ, Ricci MA, Taatjes DJ, Baumann PQ, Reese JC, Leavitt BJ, Absher M, Sobel BE, Changes in arterial expression of fibrinolylic system proteins in atherogenesis. Arterioscler Thromb Vase Biol. 1997;17:3294-3301.
12. Schneider DJ, Absher PM, Russell JC, Sobel BE. Increased expression of plasminogen activator inhibitor type 1 (PAI-1) predisposes to atherosclerosis in corpulent, insulin resistant (JCR:LA-cp) rats that mimic derangements in type 2 diabetes. J Am Coll Cardiol. 1997;29:229A. Abstract.
13. Absher PM, Schneider DJ, Russell JC, Sobel BE. Increased proliferation of explanted vascular smooth muscle cells: a marker presaging atherogenesis. Atherosclerosis. 1997;131:187-194.
14. Samad F, Loskutoff DJ, Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 1996;2:568-582.
15. Samad F, Yamamoto K, Loskutoff DJ, Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-α and lipopolysaccharide. J Clin Invest. 1996;97:37-46.
16. Taatjes DJ, Wadsworth M, Absher PM, Sobel BE, Schneider DJ. Immunoelectron microscopic localization of plasminogen activator inhibitor type 1 (PAI-1) in smooth muscle cells from morphologically normal and atherosclerotic human arteries. Ultrastruct Pathol. 1997;21:527-536.
17. Sobel BE. Altered fibrinolysis and platelet function in the development of vascular complications of diabetes. Curr Opin Endocrinol Diabetes. 1996;3:355-360.
18. Jujan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients: relationship with plasma insulin. Thromb Haemoat. 1989;61:370-373.
19. Ehrmann DA, Schneider DJ, Sobel BE, Cavaghan MK, Imperial J, Rosenfield RL, Polonsky KS. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:2108-2116.
20. Calles-Escandon J, Ballor D, Harvey-Berino J, Ades P, Tracy R, Sobel BE, Amelioration of the inhibition of fibrinolysis in obese elderly subjects by moderate caloric restriction. Am J Clin Nutr. 1996;64:7-11.
21. Nordt TK, Schneider, Sobel BE, Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin: a potential risk factor for vascular disease. Circulation. 1994;89:321-330.
22. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation. 1995;91:764-770.
23. Jain SK, Nagi DK, Slavin BM, Lumb PJ, Yudkin JS. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med. 1993;10:27-32.
24. Schneider DJ, Sobel BE, Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins. and fatty acids. Coron Artery Dis. 1996;7:813-817.